Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients
Neoplasia
Acute leukemia
Acute lymphoblastic leukemias
Molecularbiology
Molecular hematology
Journal
Turkish journal of haematology : official journal of Turkish Society of Haematology
ISSN: 1308-5263
Titre abrégé: Turk J Haematol
Pays: Turkey
ID NLM: 9606065
Informations de publication
Date de publication:
23 02 2022
23 02 2022
Historique:
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
30
3
2022
Statut:
ppublish
Résumé
Based on the immunophenotype, acute lymphoblastic leukemia (ALL) can be categorized into B-cell or T-cell lineages. B-cell precursor ALL (BCP-ALL) cases show various genetic/molecular abnormalities, and varying frequencies of chimeric fusion transcripts in BCP-ALL cases are reported from different parts of the world. We studied the immunophenotypic aberrancy profiles of a large number of BCP-ALL cases with respect to various common chimeric fusion transcripts. Flow cytometric immunophenotyping and multiplex reverse-transcription polymerase chain reaction assays were performed for 986 BCP-ALL cases. Among 986 BCP-ALL cases, the incidence of various fusion transcripts was 38.36% in adult cases and 20.68% in pediatric cases. Adult BCP-ALL patients with t(9;22)( Aberrant myeloid markers were frequently expressed among BCP-ALL patients with the t(9;22)( Akut lenfoblastik lösemi (ALL), immünofenotipe dayalı olarak, B-hücre veya T-hücre kökenli olarak kategorize edilebilir. B-hücre prekürsör ALL (BCP-ALL) olguları çeşitli genetik/moleküler anormallikler gösterir ve BCP-ALL olgularındaki kimerik füzyon transkriptlerinin değişik frekansları dünyanın farklı yerlerinden rapor edilmiştir. Çok sayıda BCP-ALL olgusunun ortak yaygın kimerik füzyon transkriptlerine göre immünofenotipik anormallik profillerini inceledik. 986 BCP-ALL olgusu için akım sitometrik immünofenotipleme ve multipleks ters-transkripsiyon polimeraz zincir reaksiyonu çalışmaları yapıldı. 986 BCP-ALL olgusu arasında çeşitli füzyon transkriptlerinin insidansı yetişkin olgularda %38,36 ve pediatrik olgularda %20 ,68 idi. T(9;22)( Anormallik myeloid belirteçler, t(9;22)(
Autres résumés
Type: Publisher
(tur)
Akut lenfoblastik lösemi (ALL), immünofenotipe dayalı olarak, B-hücre veya T-hücre kökenli olarak kategorize edilebilir. B-hücre prekürsör ALL (BCP-ALL) olguları çeşitli genetik/moleküler anormallikler gösterir ve BCP-ALL olgularındaki kimerik füzyon transkriptlerinin değişik frekansları dünyanın farklı yerlerinden rapor edilmiştir. Çok sayıda BCP-ALL olgusunun ortak yaygın kimerik füzyon transkriptlerine göre immünofenotipik anormallik profillerini inceledik.
Identifiants
pubmed: 34617433
doi: 10.4274/tjh.galenos.2021.2021.0326
pmc: PMC8886275
doi:
Substances chimiques
Oncogene Proteins, Fusion
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-12Références
Int J Hematol. 2009 May;89(4):431-437
pubmed: 19322628
Oman Med J. 2021 Jan 31;36(1):e218
pubmed: 33585041
Am Soc Clin Oncol Educ Book. 2016;35:e314-22
pubmed: 27249738
Acta Haematol. 2012;128(1):17-9
pubmed: 22572394
Am J Clin Pathol. 2009 Dec;132(6):940-9
pubmed: 19926587
Korean J Lab Med. 2010 Feb;30(1):1-8
pubmed: 20197715
Blood. 1997 Jul 15;90(2):571-7
pubmed: 9226156
Int J Lab Hematol. 2008 Aug;30(4):286-91
pubmed: 18665825
Br J Haematol. 1999 Jun;105(4):876-82
pubmed: 10554796
Med Pediatr Oncol. 2002 Jul;39(1):12-7
pubmed: 12116073
Indian Pediatr. 2014 Feb;51(2):152-3
pubmed: 24632701
Hematology Am Soc Hematol Educ Program. 2010;2010:21-9
pubmed: 21239766
Cancer Biol Ther. 2012 Oct;13(12):1158-64
pubmed: 22892848
Leukemia. 1998 Jun;12(6):996-7
pubmed: 9639432
Asia Pac J Clin Oncol. 2015 Dec;11(4):293-8
pubmed: 26264145
Leukemia. 2003 Jun;17(6):1192-3
pubmed: 12764391
J Genet. 2011 Aug;90(2):349-53
pubmed: 21869488
J Cancer Res Ther. 2016 Apr-Jun;12(2):620-6
pubmed: 27461621
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):174-80
pubmed: 25696852
Cytometry B Clin Cytom. 2009 May;76(3):199-205
pubmed: 18803279
J Oncol. 2012;2012:135186
pubmed: 23227046
J Pharmacol Pharmacother. 2016 Apr-Jun;7(2):62-71
pubmed: 27440950
Mediterr J Hematol Infect Dis. 2019 Mar 01;11(1):e2019017
pubmed: 30858955
J Pediatr Hematol Oncol. 2013 Apr;35(3):170-3
pubmed: 23511488
Curr Hematol Malig Rep. 2016 Aug;11(4):253-64
pubmed: 27101015
N Engl J Med. 2014 Sep 11;371(11):1005-15
pubmed: 25207766